Bevacizumab Biosimilar Demonstrates Therapeutic Equivalence to Reference Drug in Patients with Late-Stage NSCLC

TOP - October 2021 Vol 14, No 6 | Biosimilars - ESMO

Results from a phase 3 clinical trial showed equivalence between the bevacizumab biosimilar, BCD-021, and the reference product, bevacizumab (Avastin), in terms of overall response rate (ORR) in patients with stage IIIB or IV nonsquamous non–small-cell lung cancer. Safety, pharmacokinetics (PK), and immunogenicity parameters were also comparable between the 2 agents. These findings were reported in a poster presentation by Natalia Fadeeva, MD, PhD, Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine, Russia, and colleagues during the 2021 European Society for Medical Oncology virtual meeting.

A total of 357 patients from Russia and India were randomized 1:1 and 2:1, respectively, to receive either BCD-201 or reference bevacizumab plus paclitaxel and carboplatin once every 3 weeks for 6 cycles. Patients had at least 1 computed tomography scan after initiation of therapy. At week 18, patients who had stable disease or who acheived a complete or partial response were given the opportunity to continue treatment with BCD-021 until disease progression, death, or intolerable toxicity.

The primary efficacy end point was ORR based on responses achieved by week 19 and confirmed 4 weeks thereafter. The primary PK end point was AUC(0-t) after first infusion. Secondary end points included safety, PK, and immunogenicity.

Results showed an ORR of 34.6% in the BCD-021 group and 33.8% in the reference bevacizumab group. Complete response rates were 1.5% and 0.7%, respectively, and partial response rates were 33.2% and 33.1%, respectively. The percentage of patients with stable disease in the biosimilar and reference drug groups were 31.7% and 33.8%, respectively.

PK parameters and the incidence of antidrug antibodies were also comparable between BCD-021 and reference bevacizumab.

The rates of any grade adverse events (AEs) were 91.3% in the BCD-021 group versus 93.4% in the reference bevacizumab group. Serious AEs were observed in 13.6% and 10.9% of patients, respectively. The most frequently occurring AEs were anemia, neutropenia, and alopecia.

“This study demonstrated equivalence between BCD-021 and bevacizumab in terms of ORR risk difference and risk ratio. PK equivalence of BCD-021 and bevacizumab was also confirmed. Safety and immunogenicity parameters were comparable between BCD-021 and bevacizumab,” noted Dr Fadeeva and colleagues in their poster.

Related Items
Study Shows Increase in Biosimilar Use Among Oncology Providers
Anne Rowe
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in Best Practices, Biosimilars
5-Year Follow-Up Study Confirms Safety and Efficacy of Trastuzumab Biosimilar in Patients with HER2-Positive Breast Cancer
William King
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in ESMO
Targeted Therapy with Olaparib Beneficial in Metastatic Prostate Cancer with Gene Mutations
Phoebe Starr
Web Exclusives published on February 24, 2020 in ESMO
Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care
Phoebe Starr
Web Exclusives published on October 28, 2019 in ESMO, Breast Cancer
Adjuvant Innovative Peptide Vaccine Therapy Shows Promising Activity in Early-Stage Triple Negative Breast Cancer
Conference Correspondent  published on November 5, 2018 in ESMO 2018 Wrap Up, ESMO
Breaking News from the 2018 Meeting of the European Society for Medical Oncology (ESMO)
Conference Correspondent  published on October 22, 2018 in ESMO 2018 Wrap Up, ESMO
A Meta-Analysis to Evaluate the Risk for Fatigue in Patients Treated with Olaparib for Advanced Cancer
Conference Correspondent  published on October 22, 2018 in ESMO 2018, ESMO
A Phase 1b and Randomized Phase 2 Trial of Pazopanib with or Without Fosbretabulin in Advanced Recurrent Ovarian Cancer
Conference Correspondent  published on October 22, 2018 in ESMO 2018, ESMO
The Efficacy of Apatinib Treatment for Advanced Ovarian Cancer After Second-Line Chemotherapy Failure
Conference Correspondent  published on October 22, 2018 in ESMO 2018, ESMO
Oregovomab and Nivolumab as a Combinatorial Immunotherapy Strategy for Recurrent Epithelial Ovarian Cancer
Conference Correspondent  published on October 22, 2018 in ESMO 2018, ESMO
Last modified: November 8, 2021